How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

12,203 results for

Prostate Cancer Staging

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

141. Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer (Full text)

Overexpression of a novel candidate oncogene KIF14 correlates with tumor progression and poor prognosis in prostate cancer Prostate cancer (PCa) is the second leading cause of death from cancer in men. The mechanism underlying tumorigenesis and development of PCa is largely unknown. Here, we identified Kinesin family member 14 (KIF14) as a novel candidate oncogene in PCa. We found that KIF14 was overexpressed in multiple PCa cell lines and primary PCa tissues. Knockdown of KIF14 in DU145 (...) and PC3 prostate cancer cells suppressed cell proliferation, induced cell cycle arrest and apoptosis. Transcriptome analysis by RNA-sequencing demonstrated that KIF4 suppression led to transcriptional changes of genes involved in p53 and TGF-beta signaling pathway. In addition, upregulated expression of GADD45A, GADD45B, p21, PIDD and Shisa5, which contribute to growth arrest and apoptosis induction, and downregulated CCNB1 that promotes cell cycle progression were confirmed by quantitative real-time

2017 Oncotarget PubMed abstract

142. RETRACTED ARTICLE: Liver X receptors constrain tumor development and metastasis dissemination in PTEN-deficient prostate cancer (Full text)

RETRACTED ARTICLE: Liver X receptors constrain tumor development and metastasis dissemination in PTEN-deficient prostate cancer Advanced prostate cancer (PCa) is a clinical challenge as no curative therapeutic is available. In this context, a better understanding of metastasis and resistance mechanisms in PCa is an important issue. As phosphatase and tensin homolog (PTEN) loss is the most common genetic lesion in such cancer, we investigate human data sets for mechanisms that can constrain (...) cancer evolution in this setting. Here we report a liver X receptor (LXR) signature, which tightly correlates with PTEN loss, in PCa. Accordingly, the LXR pathway is deregulated in prostate carcinomas in Pten-null mice. Genetic ablation of LXRs in Pten-null mice, exacerbates PCa invasiveness and metastatic dissemination, which involves mesenchymal transition and accumulation of matrix metalloproteinases. Mechanistically, PTEN deletion governed LXR transcriptional activity through deregulation

2017 Nature communications PubMed abstract

143. LncRNA XIST acts as a tumor suppressor in prostate cancer through sponging miR-23a to modulate RKIP expression (Full text)

LncRNA XIST acts as a tumor suppressor in prostate cancer through sponging miR-23a to modulate RKIP expression Accumulating evidences have indicated that aberrant expression of long non-coding RNAs (LncRNAs) is tightly associated with cancer development. Previous studies have reported that lncRNA XIST regulates tumor malignancies in several cancers. However, the underlying mechanism of XIST in prostate cancer remains unclear. In the current study, we found that XIST was down-regulated (...) in prostate cancer specimens and cell lines. Low expression of XIST was correlated with poor prognosis and advanced tumor stage in prostate cancer patients. In gain and loss of function assays, we confirmed that XIST suppressed cellular proliferation and metastasis in prostate cancer both in vitro and in vivo. Furthermore, we found that XIST negatively regulates the expression of miR-23a and subsequently promotes RKIP expression at post-transcriptional level. Consequently, we investigated the correlation

2017 Oncotarget PubMed abstract

144. Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer (Full text)

compared to other cancer types, which may account for immunotherapeutic resistance. This hypothesis also implies that select types of prostate tumors may be differentially responsive to immune-based strategies and that the clinical stage, pathological grade and underlying genetic landscape may be important criteria in identifying tumors that respond to immune therapies. One strategy is to target oncogenic driver pathways in combination with immunotherapies with the goal of overcoming tumor immunity (...) Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer Immunotherapy is being tested intensively in clinical trials for prostate cancer; it includes immune checkpoint inhibition, prostate specific antigen (PSA) vaccines and dendritic cell-based strategies. Despite increasing evidence for clinical responses, the consensus of multiple trials is that prostate cancers are poorly responsive to immunotherapy. Prostate cancer has a high degree of pathological and genetic heterogeneity

2017 International journal of molecular sciences PubMed abstract

145. miR-30e* is overexpressed in prostate cancer and promotes NF-κB-mediated proliferation and tumor growth (Full text)

miR-30e* is overexpressed in prostate cancer and promotes NF-κB-mediated proliferation and tumor growth According to the CDC prostate cancer (CaP) has the highest incidence and second highest mortality rate amongst cancers in American men. Constitutive NF-κB activation is a hallmark of CaP and this pathway drives many pro-tumorigenic characteristics of CaP cells, including cell proliferation and survival. An activated NF-κB gene signature is predictive of CaP progression and biochemical (...) of miR-30e* yet the expression and oncological impact of miR-30e* in CaP is unknown. We report that miR-30e* expression is elevated in multiple murine models of CaP and is most pronounced in late stage disease. miR-30e* drives CaP proliferation and tumor growth through inhibition of IκBα, which results in chronic activation of NF-κB. Additionally, we show that inhibition of miR-30e* improves chemotherapeutic control of CaP. Thus, miR-30e* may prove to be a novel clinical target whose inhibition leads

2017 Oncotarget PubMed abstract

146. Trans-rectal Focal Microwave Ablation of the Index Tumor in Patients With Low-risk Prostate Cancer

Posted : March 18, 2019 Sponsor: Assistance Publique - Hôpitaux de Paris Information provided by (Responsible Party): Assistance Publique - Hôpitaux de Paris Study Details Study Description Go to Brief Summary: The purpose of this study is to determine if trans-rectal microwave ablation of the index tumor of patients with low-risk prostate cancer is sufficiently precise and safe, using MRI-transrectal ultrasound image registration. Condition or disease Intervention/treatment Phase Low-Risk Prostate (...) Trans-rectal Focal Microwave Ablation of the Index Tumor in Patients With Low-risk Prostate Cancer Trans-rectal Focal Microwave Ablation of the Index Tumor in Patients With Low-risk Prostate Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove

2017 Clinical Trials

147. Expression of Molecular Markers in Circulating Tumor Cells of Metastatic Castration-Resistant Prostate Cancer

for additional information Studies a U.S. FDA-regulated Drug Product: No Studies a U.S. FDA-regulated Device Product: No Product Manufactured in and Exported from the U.S.: Yes Keywords provided by Bo Dai, Fudan University: Metastatic Castration-Resistant Prostate Cancer circulating tumor cells Prognosis Liquid biopsy Additional relevant MeSH terms: Layout table for MeSH terms Prostatic Neoplasms Neoplastic Cells, Circulating Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital (...) : NCT03089099 Recruitment Status : Recruiting First Posted : March 24, 2017 Last Update Posted : May 1, 2017 See Sponsor: Fudan University Information provided by (Responsible Party): Bo Dai, Fudan University Study Details Study Description Go to Brief Summary: As prostate cancer progresses into castration-resistant stage from initial hormone-sensitive status, the biological behavior of tumor cells that dissociated from primary lesions changed. Considered a "liquid biopsy," these circulating tumor cells

2017 Clinical Trials

148. Obesity as a Risk Factor for Unfavorable Disease in Low-risk Prostate Cancer and Its Relationship with Anatomic Location of Tumor. (Abstract)

Obesity as a Risk Factor for Unfavorable Disease in Low-risk Prostate Cancer and Its Relationship with Anatomic Location of Tumor. We investigated the influence of obesity on unfavorable disease in men with low risk prostate cancer eligible for active surveillance and verified the underlying relationship with tumor location.We analyzed the records of 890 patients with biopsy Gleason score 6 who underwent radical prostatectomy for prostate cancer via multicore (12 or more) biopsy at our (...) institution. Unfavorable disease was defined as primary Gleason pattern 4 or greater, or pathological stage T3 or greater. Multivariate logistic regression analysis was performed to identify factors associated with unfavorable disease. The association of unfavorable disease with anatomical location of the index tumor was assessed.Overall 216 (24.3%), 544 (61.1%) and 130 men (14.6%) had a body mass index of less than 23 (normal), 23 to 27.5 (overweight) and 27.5 kg/m2 or greater (obese), respectively

2017 Journal of Urology

149. Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer. (Abstract)

Circulating Tumor Cells as a Marker for Progression-free Survival in Metastatic Castration-naïve Prostate Cancer. Analysis of circulating tumor cells (CTC) is a promising prognostic marker in castration-resistant prostate cancer (CRPC). The aim of this study was to investigate CTC detection and phenotyping as prognostic biomarkers for response to primary androgen deprivation therapy (ADT) of metastatic prostate cancer (PC).PC patients presenting with a prostate specific antigen (PSA) >80 ng/ml (...) and/or metastatic disease, intended for ADT were enrolled in the study. CTCs were analysed for expression of PSA prostate specific membrane antigen (PSMA) and epidermal growth factor receptor (EGFR) before and three months after ADT and related to progression.At inclusion, 46 out of 53 patients (87%) were CTC-positive with a sensitivity and specificity for distant metastases (M1) of 98% and 75%, respectively. In patients with M1-disease, EGFR-detection in CTC was an independent prognostic marker for progression

2017 Prostate

150. Diagnosis, Staging and Treatment of Patients with Prostate Cancer

in Ireland, 2010-2012 87 Figure 7 Five year net survival: Prostate Cancer in Ireland 88 Figure 8 Economic Literature Review Results 1377 | A National Clinical Guideline | Diagnosis, staging and treatment of patients with prostate cancer Cancer is a major healthcare challenge. Each year in Ireland, approximately 19,000 people are diagnosed with malignant cancer. Cancer is the second leading cause of death in Ireland after diseases of the circulatory system. Deaths from cancer averaged about 8,800 deaths (...) at three levels. (C) 2.4.2.1 For determining tumour extent in prostate core biopsies, when there are multiple foci of prostate cancer in a single core separated by benign intervening stroma, it is suggested that the collapsing method is used (i.e. where intervening benign tissue is excluded from the measurement). (D) 2.4.3.1 For each biopsy site the presence of biopsies positive for carcinoma and the ISUP 2005 Gleason score should be reported. The pathologists should assign a separate Gleason score

2016 National Clinical Guidelines (Ireland)

151. Chronic obstructive pulmonary disease with short-acting inhaled pharmacotherapy increases the risk of prostate cancer: A two-stage database approach. (Full text)

Chronic obstructive pulmonary disease with short-acting inhaled pharmacotherapy increases the risk of prostate cancer: A two-stage database approach. Patients with chronic obstructive pulmonary disease (COPD) are at a higher risk of many types of cancer. However, specific investigation of the risk of prostate cancer and the influence of COPD pharmacotherapy in patients with COPD is lacking. This study investigated the risk and influence of COPD pharmacotherapy on risk of prostate cancer (...) of smoking, alcohol drinking, and body mass index in the LHID. The hazard ratio (HR) and adjusted HR were estimated. Moreover, the influence of inhaled medications and other related medication on the risk of prostate cancer was analyzed by Cox proportional hazard regression.The COPD cohort comprised 12,774 patients, and the control cohort comprised 38,322 patients (1:3). The incidence of prostate cancer was 633 per 100,000 person-years in the COPD cohort and 361 per 100,000 person-years in the control

2018 PLoS ONE PubMed abstract

152. Prostate Cancer?Pretreatment Detection, Surveillance, and Staging

, not of it” [1], the reality is that prostate cancer is second only to lung cancer as a cause of death from malignancy in American men. Specifically, in 2015, an estimated 220,800 American men were diagnosed with prostate cancer and 27,540 died of the disease [2]. In addition to the personal toll of these deaths, the direct economic cost of prostate cancer in the Unites States has been estimated at approximately $10 billion per year [3]. As with other malignancies, the primary goal during baseline evaluation (...) of prostate cancer is disease characterization; that is, establishing disease extent, both local and distant, and aggressiveness. Determination of tumor aggressiveness is ultimately the most important factor, since this drives patient outcome. Several special circumstances make the accurate baseline evaluation of prostate cancer particularly challenging: ? The currently available standard clinical tools used to evaluate prostate cancer, such as digital rectal examination, serum prostate-specific antigen

2016 American College of Radiology

153. Radical Prostatectomy and Radiation Therapy for Prostate Cancer: Clinical Effectiveness and Guidelines

: RA1061-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of radical prostatectomy for early-stage or screen-detected prostate cancer? What is the clinical effectiveness of radiation therapy for early-stage or screen-detected prostate cancer? What are the evidence-based guidelines on the use of radical prostatectomy for prostate cancer? What are the evidence-based guidelines on the use of radiation therapy (...) for prostate cancer? Key Message One health technology assessment, nine systematic reviews (including one systematic review with meta-analysis and one network meta-analysis), and four randomized controlled trials were identified regarding the clinical effectiveness of radical prostatectomy or radiation therapy for early-stage or screen-detected prostate cancer. In addition, ten evidence-based guidelines were identified regarding the use of radical prostatectomy or radiation therapy for prostate cancer

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

154. Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines

is the clinical effectiveness of cryotherapy for early-stage or screen-detected prostate cancer? What are the evidence-based guidelines on the use of cryotherapy for prostate cancer? Key Message Four systematic reviews (including one systematic review with meta-analysis) were identified regarding the clinical effectiveness of cryotherapy for early-stage or screen-detected prostate cancer. In addition, five evidence-based guidelines were identified regarding the use of cryotherapy for prostate cancer. Files (...) Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines Cryotherapy for Prostate Cancer: Clinical Effectiveness and Guidelines Last updated: October 3, 2019 Project Number: RA1062-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

155. Molecular Biomarkers in Localized Prostate Cancer

attained information (ie, PSA, Grade Group, and/or clinical stage). The goal of a biomarker is to achieve any, or ideally all, of the following: estimate the likelihood of a disease characteristic being present or absent, more accurately determine prognosis, or provide the probability of response to a specific treatment. To evaluate the localized prostate cancer biomarker studies to date, ASCO formed an Expert Panel. The potential role of molecular biomarkers in 4 clinical scenarios was addressed (...) and might benefit from refined risk classification. Literature review, analysis, and clinical interpretation. Twenty studies - were obtained (Data Supplement 4). Management decisions in localized prostate cancer are generally centered around the use of prognostic clinical and pathologic factors to assess tumor aggressiveness and natural history. However, the prognostic accuracy of an isolated clinicopathologic variable—Grade Group, clinical stage, and PSA—is limited. Multivariable models, such as NCCN

2020 American Society of Clinical Oncology Guidelines

156. Abiraterone acetate (Zytiga) - for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer

evidence, the output from the PACE process, and application of the appropriate SMC modifiers, the Committee accepted abiraterone for use in NHSScotland. Other data were also assessed but remain confidential.* Additional information: guidelines and protocols The National Institute for Health and Care Excellence (NICE), published ‘Prostate cancer: diagnosis and management’ guideline number 131 in 2019. This guideline stratifies the risk of disease according to PSA levels, Gleason score and clinical stage (...) short form, observed as two consecutive evaluations), the median time was not reached in the abiraterone group compared to 16.6 months in the placebo group (HR 0.69, 95% confidence interval [CI]: 0.58 to 0.83). 4 STAMPEDE is an ongoing open-label, multi-arm, multi-stage phase II/III study that aims to assess varied therapeutic regimens in the management of high risk locally advanced or metastatic hormone- naïve prostate cancer. The primary outcome was overall survival and PFS was assessed

2020 Scottish Medicines Consortium

157. EANM Guideline/SNMMI Procedure Standard on [18F]Fluciclovine PET/CT for Prostate Cancer Imaging

, Nieh PT, Yu W, Nye JA, Master V, et al. Initial experience with the radiotracer anti-1-amino-3- 18 F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med. 2007;48:56–63. 6. Evans JD, Jethwa KR, Ost P, Williams S, Kwon ED, Lowe VJ, et al. Prostate cancer-specific PET radiotracers: a review on the clinical utility in recurrent disease. PractRadiatOncol. 2018;8:28–39. 7. Okudaira H, Shikano N, Nishii R, Miyagi T, Yoshimoto M, Kobayashi M, et al. Putative transport (...) imaging in the staging of biochemically recurrent prostate cancer. J Urol. 2017;197:676–83. 24. Schuster DM, Nieh PT, Jani AB, et al. Anti-3-[( 18 )F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. J Urol. 2014;191:1446–53. 25. Nanni C, Zanoni L, Pultrone C, et al. ( 18 )F-FACBC (anti1-amino-3-( 18 )F

2020 Society of Nuclear Medicine and Molecular Imaging

158. Bone Health and Bone-targeted Therapies for Prostate Cancer

for Prostate Cancer guideline. This guideline included recommendations across a relatively broad clinical spectrum within prostate cancer. Topics addressed ranged from management of osteoporotic fracture risk in nonmetastatic disease to management of men with castration-resistant prostate cancer metastatic to bone. ASCO has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations. METHODS The Bone Health and Bone-Targeted (...) -targeted therapies for prostate cancer. The CCO practice recommendations are drawn from data provided by randomized controlled trials (RCT) and systematic reviews of bone-targeted therapies in men with prostate cancer in a variety of settings. Relevant clinical risks range from osteoporotic fractures associated with androgen-deprivation therapy (ADT) to morbidity and death as a result of progression of bone-metastatic castration-resistant disease. In this document, the ASCO Expert Panel (Appendix

2020 American Society of Clinical Oncology Guidelines

159. Incidental Detection of Occult Thyroid Carcinoma with 11C-Choline PET/CT for High Risk Prostate Cancer (Full text)

Incidental Detection of Occult Thyroid Carcinoma with 11C-Choline PET/CT for High Risk Prostate Cancer We report a case of a 65-year-old male patient with high-risk prostate cancer, re-staged with 11C-choline positron emission tomography/computed tomography (PET/CT) for prostate specific antigen recurrences 3 years after radical prostatectomy and adjuvant radiation therapy. In addition to 2 suspicious presacral lymph nodes which were resected and proven to be metastatic, PET/CT revealed a very (...) high uptake in a calcified thyroid nodule. Evaluation with fine needle aspiration was suspicious for thyroid carcinoma and the patient underwent total thyroidectomy, confirming a non-metastatic encapsulated follicular variant of papillary thyroid carcinoma. To our knowledge, this is the first report of a thyroid cancer diagnosed with 11C-choline PET/CT for prostate cancer staging.

2017 Current urology PubMed abstract

160. External Beam Radiation and Brachytherapy for Prostate Cancer: Is It a Possible Trigger of Large Cell Neuroendocrine Carcinoma of the Urinary Bladder? (Full text)

, and generally presents in an advanced stage with poor prognosis compared to transitional cell bladder carcinoma. There is no standardized treatment regimen because of the rarity of the disease. Herein, we present a case of 72-year-old male patient with previously treated prostate cancer, who received external beam radiation therapy and high dose brachytherapy, presenting with intermittent hematuria. Cystoscopy and transurethral resection of bladder tumor (TURBT) were performed. The histopathology (...) External Beam Radiation and Brachytherapy for Prostate Cancer: Is It a Possible Trigger of Large Cell Neuroendocrine Carcinoma of the Urinary Bladder? Neuroendocrine tumors commonly involve the respiratory and gastrointestinal systems. Primary genitourinary neuroendocrine tumors are rare, accounting for less than 1% of all bladder carcinomas. Four histopathologic subtypes have been described. Among those, large cell neuroendocrine carcinoma (LCNEC) is the least common, is more aggressive

2017 Case reports in oncological medicine PubMed abstract

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>